Key facts
- Oral Genome’s last known valuation is $19.9M (Jan 2025).
- It has raised $4.4M across 2 recorded rounds; the latest was Seed Round ($3.1M) in Jan 2025.
- Notable investors include Plug and Play Tech Center, Springboard Enterprises, LvlUp Ventures, American Dental Association, Haleon — 9 tracked in total.
- Oral Genome has filed 4 Form Ds with the SEC since 2021, most recently Jan 2025 ($3.1M sold to 37 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Oral Genome
Funding rounds
2 roundsAbout Oral Genome
Developer of oral health technology designed to identify potential dental health issues. The company provides a dental testing kit that analyzes the oral microbiome and biomarkers affecting cavity and disease risk, enabling individuals to receive personalized recommendations and take preventive actions to improve oral health and reduce the likelihood of common dental problems.
- Industry
- Diagnostic Equipment
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2021
- Employees
- 10
- Website
- oralgenome.com/
- Ownership
- Privately Held (backing)
Oral Genome doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oral Genome shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oral Genome in its N-PORT filings yet. We sweep new filings monthly.